Cullen/Frost Bankers’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-11
| Closed | -$343 | – | 1550 |
|
|
2025
Q4 | $343 | Buy |
+11
| New | +$271 | ﹤0.01% | 1374 |
|
|
2025
Q1 | – | Sell |
-21
| Closed | -$463 | – | 1471 |
|
|
2024
Q4 | $463 | Buy |
+21
| New | +$382 | ﹤0.01% | 1294 |
|
|
2023
Q2 | – | Sell |
-203
| Closed | -$1.8K | – | 1267 |
|
|
2023
Q1 | $1.8K | Sell |
203
-262
| -56% | -$2.59K | ﹤0.01% | 1108 |
|
|
2022
Q4 | $4.24K | Hold |
465
| – | – | ﹤0.01% | 983 |
|
|
2022
Q3 | $4K | Buy |
465
+203
| +77% | +$1.79K | ﹤0.01% | 1026 |
|
|
2022
Q2 | $2K | Hold |
262
| – | – | ﹤0.01% | 1010 |
|
|
2022
Q1 | $2K | Hold |
262
| – | – | ﹤0.01% | 1060 |
|
|
2021
Q4 | $2K | Hold |
262
| – | – | ﹤0.01% | 1085 |
|
|
2021
Q3 | $3K | Hold |
262
| – | – | ﹤0.01% | 1154 |
|
|
2021
Q2 | $3K | Hold |
262
| – | – | ﹤0.01% | 1149 |
|
|
2021
Q1 | $3K | Sell |
262
-109
| -29% | -$1.25K | ﹤0.01% | 1013 |
|
|
2020
Q4 | $4K | Hold |
371
| – | – | ﹤0.01% | 970 |
|
|
2020
Q3 | $3K | Hold |
371
| – | – | ﹤0.01% | 1000 |
|
|
2020
Q2 | $5K | Sell |
371
-8,618
| -96% | -$97.5K | ﹤0.01% | 967 |
|
|
2020
Q1 | $81K | Buy |
8,989
+8,618
| +2,323% | +$88.3K | ﹤0.01% | 467 |
|
|
2019
Q4 | $4K | Sell |
371
-900
| -71% | -$8.04K | ﹤0.01% | 970 |
|
|
2019
Q3 | $9K | Hold |
1,271
| – | – | ﹤0.01% | 844 |
|
|
2019
Q2 | $12K | Sell |
1,271
-1,279
| -50% | -$15.4K | ﹤0.01% | 808 |
|
|
2019
Q1 | $40K | Buy |
+2,550
| New | +$45K | ﹤0.01% | 595 |
|
|
2017
Q4 | – | Sell |
-11,331
| Closed | -$199K | – | 396 |
|
|
2017
Q3 | $199K | Sell |
11,331
-725
| -6% | -$16.3K | 0.01% | 375 |
|
|
2017
Q2 | $401K | Buy |
12,056
+555
| +5% | +$17.2K | 0.01% | 296 |
|
|
2017
Q1 | $369K | Buy |
11,501
+344
| +3% | +$11.7K | 0.01% | 305 |
|
|
2016
Q4 | $405K | Buy |
11,157
+1,737
| +18% | +$69.4K | 0.01% | 296 |
|
|
2016
Q3 | $433K | Sell |
9,420
-1,418
| -13% | -$74K | 0.02% | 279 |
|
|
2016
Q2 | $545K | Buy |
10,838
+630
| +6% | +$33.5K | 0.02% | 269 |
|
|
2016
Q1 | $546K | Sell |
10,208
-122
| -1% | -$7.16K | 0.02% | 269 |
|
|
2015
Q4 | $678K | Sell |
10,330
-352
| -3% | -$21.8K | 0.03% | 257 |
|
|
2015
Q3 | $603K | Buy |
10,682
+36
| +0.3% | +$2.33K | 0.02% | 265 |
|
|
2015
Q2 | $629K | Sell |
10,646
-2,069
| -16% | -$128K | 0.02% | 279 |
|
|
2015
Q1 | $793K | Sell |
12,715
-15,664
| -55% | -$911K | 0.03% | 263 |
|
|
2014
Q4 | $1.63M | Sell |
28,379
-22,605
| -44% | -$1.26M | 0.06% | 210 |
|
|
2014
Q3 | $2.74M | Sell |
50,984
-9,350
| -15% | -$495K | 0.11% | 166 |
|
|
2014
Q2 | $3.16M | Sell |
60,334
-6,871
| -10% | -$351K | 0.13% | 164 |
|
|
2014
Q1 | $3.55M | Buy |
67,205
+7,417
| +12% | +$343K | 0.15% | 154 |
|
|
2013
Q4 | $2.4M | Sell |
59,788
-5,065
| -8% | -$199K | 0.11% | 175 |
|
|
2013
Q3 | $2.45M | Sell |
64,853
-12,901
| -17% | -$503K | 0.12% | 168 |
|
|
2013
Q2 | $3.05M | Buy |
+77,754
| New | +$3.03M | 0.16% | 160 |
|
Other funds holding TEVA
HIIFS
PF
MMH
CI
MIFH
LIM
Cullen/Frost Bankers's TEVA Position: Q1 2026 in Review
Cullen/Frost Bankers sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 11 shares — an estimated $343 sold.
Cullen/Frost Bankers first reported a position in TEVA in Q2 2013 and held it in 37 quarters. The position peaked at $3.55M in Q1 2014. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.
- Cullen/Frost Bankers reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Cullen/Frost Bankers sold 11 Teva Pharmaceuticals shares in Q1 2026, an estimated $343.
- Cullen/Frost Bankers first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 37 quarters.
- Cullen/Frost Bankers's Teva Pharmaceuticals position peaked at $3.55M in Q1 2014.
- 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.
Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.